Edition:
United Kingdom

Blueprint Medicines Corp (BPMC.OQ)

BPMC.OQ on NASDAQ Stock Exchange Global Select Market

66.17USD
17 Nov 2017
Change (% chg)

$-0.57 (-0.85%)
Prev Close
$66.74
Open
$66.29
Day's High
$68.04
Day's Low
$65.39
Volume
117,493
Avg. Vol
144,087
52-wk High
$74.42
52-wk Low
$25.08

Latest Key Developments (Source: Significant Developments)

Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors showing strengthened clinical activity across spectrum of kit and pdgfrα genotypes.Blueprint Medicines Corp - ‍new cohort in second-line gist added to ongoing phase 1 trial​.Blueprint Medicines Corp - ‍global, randomized phase 3 trial in third-line gist on track to initiate in first half 2018​.  Full Article

Blueprint Medicines Q3 loss per share $0.96
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines reports third quarter 2017 financial results.Q3 loss per share $0.96.Q3 earnings per share view $-0.91 -- Thomson Reuters I/B/E/S.Blueprint Medicines - ‍existing cash will be sufficient to fund its operating expenses and capex requirements into H2 2019​.Blueprint Medicines - ‍plans to initiate a global, pivotal Phase 3 clinical trial of BLU-285 in third-line patients with KIT-driven GIST in H1 2018​.  Full Article

James Flynn reports 4.51 pct passive stake in Blueprint Medicines
Tuesday, 25 Oct 2016 

Blueprint Medicines Corp :James Flynn reports 4.51 percent passive stake in Blueprint Medicines Corp as of October 20 - sec filing.  Full Article

Blueprint Medicines enters into agreement, project schedule with Qiagen
Tuesday, 23 Aug 2016 

Blueprint Medicines Corp : On August 22, entered into a master collaboration agreement and a project schedule with Qiagen Manchester Limited . Co will pay Qiagen up to approximately $6.1 million over term of development program for companion diagnostic test for BLU-285 . Qiagen to develop assay as companion test to identify gastrointestinal stromal tumor patients with PDGFR D842V mutation for use with BLU-285 Source: (http://bit.ly/2by79lU) Further company coverage: [BPMC.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Blueprint Medicines reports Q2 loss per share $0.70
Tuesday, 9 Aug 2016 

Blueprint Medicines Corp : Reports second quarter 2016 financial results . Q2 earnings per share view $-0.73 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.70 .Expects that its cash, cash equivalents and investments balance will be at least $120 million at December 31, 2016.  Full Article

Blueprint Medicines files for mixed shelf offering of up to $250 mln
Tuesday, 10 May 2016 

Blueprint Medicines Corp :Files for mixed shelf offering of up to $250 million - SEC Filing.  Full Article

Blueprint Medicines posts Q1 loss of $0.57/share
Tuesday, 10 May 2016 

Blueprint Medicines Corp : Blueprint Medicines reports first quarter 2016 financial results . Q1 loss per share $0.57 . Q1 earnings per share view $-0.70 -- Thomson Reuters I/B/E/S . Collaboration revenues were $6.9 million for Q1 of 2016, as compared to $0.7 million for Q1 of 2015 . Expects that its cash, cash equivalents and investments balance will be at least $120 million at December 31, 2016 .Expects cash, cash equivalents, investments sufficient to fund operating expenses, capital expenditure requirements into late 2017.  Full Article

Blueprint Medicines Corp announces worldwide collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc
Tuesday, 15 Mar 2016 

Blueprint Medicines Corp:Entered into a worldwide collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc for discovery, development and commercialization of up to five small molecule therapeutics targeting kinases believed to be important in cancer immunotherapy.Under the terms of the agreement, Blueprint Medicines will receive an upfront cash payment of $45 million.Says also Blueprint Medicines will be eligible to receive up to an additional approximately $965 million in contingent option fees and milestone payments related to specified research, preclinical, clinical, regulatory and sales-based milestones across all five potential programs.  Full Article

Blueprint Medicines Corp enters collaboration agreement with Ventana Medical Systems
Monday, 7 Mar 2016 

Blueprint Medicines Corp:Entered into collaboration agreement with Ventana Medical Systems, Inc. a member of the Roche Group.Ventana has agreed to develop and commercialize an assay as a companion diagnostic test to identify hepatocellular carcinoma.Will pay Ventana an aggregate amount of up to approximately $12.3 million over the term of the development program.  Full Article

BRIEF-Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285

* Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors showing strengthened clinical activity across spectrum of kit and pdgfrα genotypes